Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy of topical ruxolitinib for cutaneous dermatomyositis

JAAD Case Reports(2023)10.1016/j.jdcr.2023.09.043Source: DataRank Database

Efficacy of topical ruxolitinib for cutaneous dermatomyositis is a research paper published in JAAD Case Reports (2023). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.69)OA: goldTopics (18)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Hanna Kim ORCID,Shajia Lu,Wanxia Li Tsai ORCID,Amy Kaneshiro,Alison Ehrlich ORCID

Live enrichment

PubMed:38379881 PMC:PMC10876464 OpenAlex:https://openalex.org/W4388871612

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: AR041215-02

National Institute of Environmental Health Sciences

Grant: Z01ES101074

National Institutes of Health

Grant: 1Z01ES101074-07

Environmental/genetic Risk Factors and Pathogenesis of Autoimmune Disease

National Institutes of Health

Cure JM Foundation

FWCI

1.69

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.jdcr.2023.09.043

GOLDhttps://doi.org/10.1016/j.jdcr.2023.09.043

publisherhttps://doi.org/10.1016/j.jdcr.2023.09.043

publisherhttps://api.elsevier.com/content/article/PII:S2352512623004277?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352512623004277?httpAccept=text/plain

Fields of Study

Inflammatory Myopathies and DermatomyositisDermatological and Skeletal DisordersSkin and Cellular Biology ResearchMedicine03 medical and health sciences0302 clinical medicine

Keywords

MedicineRuxolitinibDermatomyositisDermatologyHydroxychloroquineInternal medicineMyelofibrosisCoronavirus disease 2019 (COVID-19)DiseasePediatric Rheumatic DiseaseRL1-803Case Report

Sustainable Development Goals

SDG 0: Zero hunger

Efficacy of topical ruxolitinib for cutaneous dermatomyositis

FAIR Checklist

Authors (9)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)